Sanofi Ends Partnered STAT6 Degrader Program

Company Nurix Therapeutics; Sanofi Event Type Partner program discontinuation Modality Targeted protein degrader (oral) Asset SAR448272 Target STAT6 Disease Area Type 2 inflammation Summary Previously missed November 3 primary disclosure: Sanofi decided to stop the Phase 1 trial and terminate SAR448272, an oral STAT6 degrader…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *